MedicarePartD.guide

A non-government resource built from CMS public data

Xeljanz on SilverScript Choice (S5601-050)

tofacitinib

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 60 per 30 days.

$1,125.33
Patient pays / month, after deductible
$1,586.58
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

XELJANZ 5 mg Tablet, Film Coated at a preferred retail pharmacy, from the plan's negotiated price of $4,501.30 for a month. Other covered strengths are listed below.

Prior authRequired on all 5 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 5 covered strengths and forms
FormTierPatient pays / monthLimits
XELJANZ XR 11 mg Tablet, Film Coated, Extended Release5$1,576.66PA · 30 per 30 days
XELJANZ XR 22 mg Tablet, Film Coated, Extended Release5$1,576.16PA · 30 per 30 days
XELJANZ 5 mg Tablet, Film Coated5$1,125.33PA · 60 per 30 days
XELJANZ 10 mg Tablet, Film Coated5$1,576.16PA · 60 per 30 days
XELJANZ 1 mg/mL Solution5$3,341.88PA · 480 per 24 days

Other JAK inhibitors on this plan

Verify with the plan before prescribing or filling. Member services: (866)235-5660. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5601-050